

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2005-05-02** | Period of Report: **2005-04-27**
SEC Accession No. **0001144204-05-013498**

([HTML Version](#) on secdatabase.com)

FILER

AMERICAN BIO MEDICA CORP

CIK: **896747** | IRS No.: **141702188** | State of Incorporation: **NY** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **000-28666** | Film No.: **05788687**
SIC: **2834** Pharmaceutical preparations

Mailing Address
122 SMITH ROAD
KINDERHOOK NY 12106

Business Address
122 SMITH ROAD
KINDERHOOK NY 12106
5187588158

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 27, 2005

AMERICAN BIO MEDICA CORPORATION
(Exact Name of Registrant as Specified in its Charter)

New York

0-28666

14-1702188

(State or Other Jurisdiction of (Commission File Number)
Incorporation)

(IRS Employer
Identification Number)

122 Smith Road, Kinderhook, NY

12106

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (800) 227-1243

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13c-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 3.01. NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING.

On April 27, 2005, the Company received a notice from the Nasdaq Stock Market informing the Company that for the last 30 consecutive business days, the bid price of the Company's common stock has closed below the minimum \$1.00 per share requirement for continued inclusion under Marketplace Rule 4310(c)(4).

The letter stated that under Marketplace Rule 4310(c)(8)(d), the Company will be provided with 180 calendar days, or until October 24, 2005, to regain compliance with Marketplace Rule 4310(c)(4). To regain compliance, anytime before October 24, 2005, the bid price of the Company's common stock must close at \$1.00 per share or more for a minimum of 10 consecutive business days.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMERICAN BIO MEDICA CORPORATION (Registrant)

Dated: April 29, 2005

By: /s/ Keith E. Palmer

Keith E. Palmer
Chief Financial Officer

3